Patched Homolog (PTCH1) Gene as a Reliable Marker for Predicting Imatinib Response in Chronic Phase Chronic Myeloid Leukemia Patients in Correlation With Early Response to First-Line of Treatment Imatinib

被引：0
|
作者：
Rakha, Nahed Moawad [1 ]
Moahmed, Tamer [1 ]
Said, Rasha Magdy M. [1 ]
Ali, Esraa [1 ]
Abdulla, Nour Elhuda [1 ]
机构：
[1] Ain Shams Univ, Internal Med Dept, Clin Hematol Div, Fac Med, Cairo, Egypt
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CML; PTCH1; chronic phase; patched homolog gene; ELISA; imatinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-024
引用
收藏
页码：S331 / S331
页数：1
相关论文
共 50 条
  • [31] Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia
    Lin, Han-Xin
    Sjaarda, Jenny
    Dyck, Jocob
    Stringer, Randa
    Hillis, Chris
    Harvey, Maria
    Carter, Ronald
    Ainsworth, Peter
    Leber, Brian
    Pare, Guillaume
    Sadikovic, Bekim
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (04) : 360 - 366
  • [32] Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line
    Stephanie Dulucq
    Gabriel Etienne
    Stephane Morisset
    Emilie Klein
    Claudine Chollet
    Fanny Robbesyn
    Beatrice Turcq
    Isabelle Tigaud
    Sandrine Hayette
    Franck E. Nicolini
    François-Xavier Mahon
    Annals of Hematology, 2019, 98 : 1159 - 1168
  • [33] hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia
    Ben Hassine, Islem
    Gharbi, Hanene
    Soltani, Ismail
    Teber, Mouheb
    Farrah, Ahlem
    Othman, Hind Ben Hadj
    Amouri, Hassiba
    Bellaaj, Hatem
    Ben lakhal, Rayhane
    Ben Romdhane, Neila
    Abbes, Salem
    Menif, Samia
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (04) : 737 - 745
  • [34] Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?
    Song, Moo-Kon
    Chung, Joo-Seop
    Seol, Young-Mi
    Kim, Seong-Geun
    Shin, Ho-Jin
    Choi, Young-Jin
    Cho, Goon-Jae
    LEUKEMIA RESEARCH, 2009, 33 (11) : 1459 - 1462
  • [35] Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand
    Kulpeng, Wantanee
    Sompitak, Sumalai
    Jootar, Saengsuree
    Chansung, Kanchana
    Teerawattananon, Yot
    CLINICAL THERAPEUTICS, 2014, 36 (04) : 534 - 543
  • [36] OCT-1 Expression in Patients with Chronic Myeloid Leukemia: A Comparative Analysis with Respect to Response to Imatinib Treatment
    Betul Bozkurt Bulakcı
    Aynur Daglar Aday
    Basak Gurtekin
    Akif Selim Yavuz
    Sukru Ozturk
    Kivanc Cefle
    Ayse Palanduz
    Sukru Palanduz
    Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 668 - 674
  • [37] OCT-1 Expression in Patients with Chronic Myeloid Leukemia: A Comparative Analysis with Respect to Response to Imatinib Treatment
    Bulakci, Betul Bozkurt
    Aday, Aynur Daglar
    Gurtekin, Basak
    Yavuz, Akif Selim
    Ozturk, Sukru
    Cefle, Kivanc
    Palanduz, Ayse
    Palanduz, Sukru
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (04) : 668 - 674
  • [38] Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib
    Sandip Ganguly
    K. C. Lakshmaiah
    Linu Abraham Jacob
    Suresh Babu
    Lokanatha Dasappa
    K. S. Govind Babu
    Indian Journal of Hematology and Blood Transfusion, 2017, 33 : 82 - 86
  • [39] Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?
    Zackova, Daniela
    Klamova, Hana
    Dusek, Ladislav
    Muzik, Jan
    Polakova, Katerina Machova
    Moravcova, Jana
    Jurcek, Tomas
    Dvorakova, Dana
    Racil, Zdenek
    Pospisil, Zdenek
    Oltova, Alexandra
    Michalova, Kyra
    Brezinova, Jana
    Razga, Filip
    Doubek, Michael
    Cetkovsky, Petr
    Trneny, Marek
    Mayer, Jiri
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (03) : 318 - 321
  • [40] Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response
    Agirre, X
    Fontalba, A
    Andreu, EJ
    Odero, MD
    Larróyoz, MJ
    Montiel, C
    Calasanz, M
    Fernández-Luna, JL
    Prósper, F
    HAEMATOLOGICA, 2003, 88 (12) : 1425 - 1426
12345